2183-56-4

Basic information

• Product Name: hydromorphinol
• Synonyms: hydromorphinol;(5a,6a)-4,5-Epoxy-17-methylmorphinan-3,6,14-triol;14-Hydroxy-7,8-dihydromorphine;6a-Oxymorphol;7,8-Dihydro-14-hydroxymorphine;a-Oxymorphol;14-Hydroxydihydromorphine;Oxymorphol
• CAS NO: 2183-56-4
• Molecular Formula: C₁₇H₂₁NO₄
• Molecular Weight: 303.356
• EINECS: 218-565-9
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 2183-56-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 252-253 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 517.6°Cat760mmHg
• Flash Point: 266.8°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 1.53E-11mmHg at 25°C
• Refractive Index: 1.721
• PKA: 9.39±0.60(Predicted)
• CAS DataBase Reference: hydromorphinol(CAS DataBase Reference)
• NIST Chemistry Reference: hydromorphinol(2183-56-4)
• EPA Substance Registry System: hydromorphinol(2183-56-4)

Safety Data

• Hazardous Substances Data: 2183-56-4(Hazardous Substances Data)

Usage

Description

6α-Oxymorphol (CRM) (Item No. 25940) is a certified reference material categorized as an opioid. It is a metabolite of oxymorphone (Item Nos. 15911 | ISO60171). 6α-Oxymorphol is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

Uses

A metabolite of Oxymorphone

Brand name

Ifex (Bristol-Myers Squibb).

InChI:InChI=1/C17H21NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,11-12,15,19-21H,4-8H2,1H3/t11-,12+,15-,16-,17+/m0/s1

Upstream product

• 50-00-0 formaldehyd 
• 33522-95-1 noroxymorphone 
• 76-41-5 oxymorphone 
• 7183-69-9 14-hydroxydihydrocodeine 
• 4829-46-3 14-hydroxycodeine 

Downstream Products

• 72782-04-8 6β-oxymorphamine 

Relevant articles and documents

PROCESS FOR MAKING MORPHINAN-6alpha-OLS

The present invention provides a process whereby morphinan-6-ones can be converted stereospecifically to the corresponding morphinan-6α-ols by catalytic hydrogenation under basic conditions.

Probes for narcotic receptor mediated phenomena. 24. synthesis, single crystal X-ray analyses, in vitro and in vivo properties of 6α-and 6β-IODO-3,14-dihydroxy-17-methyl-4,5α-epoxymorphinans

The 6α- and 6β-iodo-3,14-dihydroxy-17-methyl-4,5α-epoxymorphinans, potential SPECT ligands, were synthesized and found to be μ-selective opioids, more potent in vitro and in vivo than their 6-hydroxy relatives. Single-crystal analysis showed that the 6α- and 6β-iodine atoms are spatially closely located although the C-ring conformations of these compounds are quite different (twist-boat form vs. chair). These epimeric conformational differences were not reflected in their binding affinities.

Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)

Fluorinated derivatives 3,14-dihydroxy-4,5α-epoxy-6β-fluoro-17-methylmorphinan (""fluorooxymorphone""; FOXY, compound 10) and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinan (CYCLOFOXY, compound 18) are prepared based upon the structures of the potent opioid agonist oxymorphone 4 and the antagonist naltrexone 11, respectively. Fluorine was introduced in the final stages of synthesis by a facile nucleophilic displacement with fluoride ion of the 6α-triflate functions in 8 and 16. The synthetic procedures were suitable for the production of the corresponding positron emitting 18 F-labeled analogs 18 F-FOXY and 18 F-CYCLOFOXY, which are useful for in vivo studies of the opioid receptor system using positron emission transaxial tomography. In addition, the tritiation of FOXY (10) to high specific activity is noted.